274 related articles for article (PubMed ID: 31030372)
21. Microdosing as a Potential Tool to Enhance Clinical Development of Novel Antibiotics: A Tissue and Plasma PK Feasibility Study with Ciprofloxacin.
Oesterreicher Z; Eberl S; Wulkersdorfer B; Matzneller P; Eder C; van Duijn E; Vaes WHJ; Reiter B; Stimpfl T; Jäger W; Nussbaumer-Proell A; Marhofer D; Marhofer P; Langer O; Zeitlinger M
Clin Pharmacokinet; 2022 May; 61(5):697-707. PubMed ID: 34997559
[TBL] [Abstract][Full Text] [Related]
22. Dose-linearity of the pharmacokinetics of an intravenous [
van Groen BD; Vaes WH; Park BK; Krekels EHJ; van Duijn E; Kõrgvee LT; Maruszak W; Grynkiewicz G; Garner RC; Knibbe CAJ; Tibboel D; de Wildt SN; Turner MA
Br J Clin Pharmacol; 2019 Oct; 85(10):2332-2340. PubMed ID: 31269280
[TBL] [Abstract][Full Text] [Related]
23. Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs.
Lappin G; Kuhnz W; Jochemsen R; Kneer J; Chaudhary A; Oosterhuis B; Drijfhout WJ; Rowland M; Garner RC
Clin Pharmacol Ther; 2006 Sep; 80(3):203-15. PubMed ID: 16952487
[TBL] [Abstract][Full Text] [Related]
24. [Impact of microdose clinical trials in the preclinical stage].
Kim S
Yakugaku Zasshi; 2014; 134(4):459-63. PubMed ID: 24694804
[TBL] [Abstract][Full Text] [Related]
25. Microdosing of protein drugs.
Rowland M
Clin Pharmacol Ther; 2016 Feb; 99(2):150-2. PubMed ID: 26452582
[TBL] [Abstract][Full Text] [Related]
26. Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates.
Fenneteau F; Poulin P; Nekka F
J Pharm Sci; 2010 Jan; 99(1):486-514. PubMed ID: 19479982
[TBL] [Abstract][Full Text] [Related]
27. [Utility of a microdose study for drug discovery and development].
Yamaura Y
Nihon Yakurigaku Zasshi; 2013 Mar; 141(3):126-30. PubMed ID: 23470476
[No Abstract] [Full Text] [Related]
28. Pediatric microdose and microtracer studies using 14C in Europe.
Turner MA; Mooij MG; Vaes WH; Windhorst AD; Hendrikse NH; Knibbe CA; Kõrgvee LT; Maruszak W; Grynkiewicz G; Garner RC; Tibboel D; Park BK; de Wildt SN
Clin Pharmacol Ther; 2015 Sep; 98(3):234-7. PubMed ID: 26095095
[TBL] [Abstract][Full Text] [Related]
29. Microdosing clinical study: pharmacokinetic, pharmacogenomic (SLCO2B1), and interaction (grapefruit juice) profiles of celiprolol following the oral microdose and therapeutic dose.
Ieiri I; Doi Y; Maeda K; Sasaki T; Kimura M; Hirota T; Chiyoda T; Miyagawa M; Irie S; Iwasaki K; Sugiyama Y
J Clin Pharmacol; 2012 Jul; 52(7):1078-89. PubMed ID: 21593283
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of microdosing strategies for studies in preclinical drug development: demonstration of linear pharmacokinetics in dogs of a nucleoside analog over a 50-fold dose range.
Sandhu P; Vogel JS; Rose MJ; Ubick EA; Brunner JE; Wallace MA; Adelsberger JK; Baker MP; Henderson PT; Pearson PG; Baillie TA
Drug Metab Dispos; 2004 Nov; 32(11):1254-9. PubMed ID: 15286054
[TBL] [Abstract][Full Text] [Related]
31. Impact of P-glycoprotein-mediated intestinal efflux kinetics on oral bioavailability of P-glycoprotein substrates.
Kwon H; Lionberger RA; Yu LX
Mol Pharm; 2004; 1(6):455-65. PubMed ID: 16028357
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetic and pharmacogenomic profiles of telmisartan after the oral microdose and therapeutic dose.
Ieiri I; Nishimura C; Maeda K; Sasaki T; Kimura M; Chiyoda T; Hirota T; Irie S; Shimizu H; Noguchi T; Yoshida K; Sugiyama Y
Pharmacogenet Genomics; 2011 Aug; 21(8):495-505. PubMed ID: 21691256
[TBL] [Abstract][Full Text] [Related]
33. Interaction of Drug or Food with Drug Transporters in Intestine and Liver.
Nakanishi T; Tamai I
Curr Drug Metab; 2015; 16(9):753-64. PubMed ID: 26630906
[TBL] [Abstract][Full Text] [Related]
34. The application of Phase 0 and microtracer approaches in early clinical development: past, present, and future.
Roffel AF; van Hoogdalem EJ
Front Pharmacol; 2024; 15():1369079. PubMed ID: 38562464
[TBL] [Abstract][Full Text] [Related]
35. Predicting human drug pharmacokinetics from in vitro permeability using an absorption-disposition model.
Fliszar KA; Hill BT; Foster N
J Pharm Sci; 2007 Aug; 96(8):2161-70. PubMed ID: 17387695
[TBL] [Abstract][Full Text] [Related]
36. Microdosing clinical study to clarify pharmacokinetic and pharmacogenetic characteristics of atorvastatin in Japanese hypercholesterolemic patients.
Lee N; Maeda K; Fukizawa S; Ieiri I; Tomaru A; Akao H; Takeda K; Iwadare M; Niwa O; Masauji T; Yamane N; Kajinami K; Kusuhara H; Sugiyama Y
Drug Metab Pharmacokinet; 2019 Dec; 34(6):387-395. PubMed ID: 31594719
[TBL] [Abstract][Full Text] [Related]
37. Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data.
Jones HM; Barton HA; Lai Y; Bi YA; Kimoto E; Kempshall S; Tate SC; El-Kattan A; Houston JB; Galetin A; Fenner KS
Drug Metab Dispos; 2012 May; 40(5):1007-17. PubMed ID: 22344703
[TBL] [Abstract][Full Text] [Related]
38. Ontogeny of oral drug absorption processes in children.
Mooij MG; de Koning BA; Huijsman ML; de Wildt SN
Expert Opin Drug Metab Toxicol; 2012 Oct; 8(10):1293-303. PubMed ID: 22686526
[TBL] [Abstract][Full Text] [Related]
39. A human microdose study of the antimalarial drug GSK3191607 in healthy volunteers.
Okour M; Derimanov G; Barnett R; Fernandez E; Ferrer S; Gresham S; Hossain M; Gamo FJ; Koh G; Pereira A; Rolfe K; Wong D; Young G; Rami H; Haselden J
Br J Clin Pharmacol; 2018 Mar; 84(3):482-489. PubMed ID: 29168205
[TBL] [Abstract][Full Text] [Related]
40. Validation of a microdose probe drug cocktail for clinical drug interaction assessments for drug transporters and CYP3A.
Prueksaritanont T; Tatosian DA; Chu X; Railkar R; Evers R; Chavez-Eng C; Lutz R; Zeng W; Yabut J; Chan GH; Cai X; Latham AH; Hehman J; Stypinski D; Brejda J; Zhou C; Thornton B; Bateman KP; Fraser I; Stoch SA
Clin Pharmacol Ther; 2017 Apr; 101(4):519-530. PubMed ID: 27943276
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
